FDA approves venetoclax in 2nd-line for patients with CLL or SLL

/0 Comments/in , , /by

 

  • FDA granted regular approval to venetoclax (VENCLEXTA,  AbbVie Inc. and Genentech Inc.) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.
You might also like
U.S.-FDA-approved-immunecheckpoint-inhibitors-e1528902398517Pertuzumab plus trastuzumab and chemotherapy FDA approved as adjuvant treatment of HER2-positive breast cancer with high recurrence score
U.S.-FDA-approved-immunecheckpoint-inhibitors-e1528902398517US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020
U.S.-FDA-approved-immunecheckpoint-inhibitors-e1528902398517Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients
U.S.-FDA-approved-immunecheckpoint-inhibitors-e1528902398517Bevacizumab in combination with carboplatin and paclitaxel FDA approved for several types of gynaecological cancers
U.S.-FDA-approved-immunecheckpoint-inhibitors-e1528902398517FDA approved rucaparib for maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer
U.S.-FDA-approved-immunecheckpoint-inhibitors-e1528902398517Adjuvant sunitinib FDA approved for renal cell carcinoma patients at high risk of recurrence following nephrectomy.
U.S.-FDA-approved-immunecheckpoint-inhibitors-e1528902398517CAR-T Axicabtagene ciloleucel FDA approved for relapsed or refractory large B-cell lymphoma
U.S.-FDA-approved-immunecheckpoint-inhibitors-e1528902398517FDA safety alert: use of immunotherapy in metastatic urothelial cancer with low PD-L1 expression
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *

FDA approved biosimilar pegfilgrastim to decrease the chance of febrile neutropenia...ASCO 2018 HCC: The ASCO18 hepatocellular cancer track summarised